Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Zimmer

Showing results (191-200 of 218) with videos related to

Pageof 22
Sort By:
European Journal of Cancer (Oxford, England : 1990)|March 13, 2022
Genetic characterization of advanced conjunctival melanoma and response to systemic treatmentGeorg C Lodde, Philipp Jansen, Inga Möller, et al.
Cancers|February 27, 2026
COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant MelanomaMichael Weichenthal, Dirk Debus, Lisa Zimmer, et al.
Journal for Immunotherapy of Cancer|June 10, 2022
Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREGCindy Franklin, Peter Mohr, Leonie Bluhm, et al.
European Journal of Cancer (Oxford, England : 1990)|August 1, 2025
Sex-specific survival in advanced metastatic melanoma - a DeCOG study on 2032 patients of the multicenter prospective skin cancer registry ADOREGAnna-Sophia Leven, Triinu Peters, Luisa Sophie Rajcsanyi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2019
Targeted Therapy in Advanced Melanoma With Rare <i>BRAF</i> MutationsChristian Menzer, Alexander M Menzies, Matteo S Carlino, et al.
Data in Brief|November 25, 2022
Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitisLeonie Müller-Jensen, Sarah Zierold, Judith M Versluis, et al.
European Journal of Cancer (Oxford, England : 1990)|September 26, 2022
Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort studyLeonie Müller-Jensen, Sarah Zierold, Judith M Versluis, et al.
European Journal of Cancer (Oxford, England : 1990)|January 21, 2023
Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanomaSelina K Wong, Steven M Blum, Xiaopeng Sun, et al.
Cancer Discovery|November 23, 2013
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanomaEliezer M Van Allen, Nikhil Wagle, Antje Sucker, et al.
European Journal of Cancer (Oxford, England : 1990)|August 24, 2025
Targeted therapy for rare BRAF-mutated melanoma: Updated multicenter analysis and launch of a publicly accessible online outcome databaseChristian Menzer, Susanne Dugas-Breit, Martin Dugas, et al.
Pageof 22

Showing results (191-200 of 218) with videos related to

Sort By:
Pageof 22
European Journal of Cancer (Oxford, England : 1990)|March 13, 2022
Genetic characterization of advanced conjunctival melanoma and response to systemic treatmentGeorg C Lodde, Philipp Jansen, Inga Möller, et al.
Cancers|February 27, 2026
COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant MelanomaMichael Weichenthal, Dirk Debus, Lisa Zimmer, et al.
Journal for Immunotherapy of Cancer|June 10, 2022
Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREGCindy Franklin, Peter Mohr, Leonie Bluhm, et al.
European Journal of Cancer (Oxford, England : 1990)|August 1, 2025
Sex-specific survival in advanced metastatic melanoma - a DeCOG study on 2032 patients of the multicenter prospective skin cancer registry ADOREGAnna-Sophia Leven, Triinu Peters, Luisa Sophie Rajcsanyi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2019
Targeted Therapy in Advanced Melanoma With Rare <i>BRAF</i> MutationsChristian Menzer, Alexander M Menzies, Matteo S Carlino, et al.
Data in Brief|November 25, 2022
Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitisLeonie Müller-Jensen, Sarah Zierold, Judith M Versluis, et al.
European Journal of Cancer (Oxford, England : 1990)|September 26, 2022
Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort studyLeonie Müller-Jensen, Sarah Zierold, Judith M Versluis, et al.
European Journal of Cancer (Oxford, England : 1990)|January 21, 2023
Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanomaSelina K Wong, Steven M Blum, Xiaopeng Sun, et al.
Cancer Discovery|November 23, 2013
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanomaEliezer M Van Allen, Nikhil Wagle, Antje Sucker, et al.
European Journal of Cancer (Oxford, England : 1990)|August 24, 2025
Targeted therapy for rare BRAF-mutated melanoma: Updated multicenter analysis and launch of a publicly accessible online outcome databaseChristian Menzer, Susanne Dugas-Breit, Martin Dugas, et al.
Pageof 22